Navigation Links
4 new drugs will change prostate cancer care
Date:2/16/2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

"It's not just chemotherapy. The drugs have different and innovative methods of action. One is a bone protective agent; another's a more effective hormone agent; another is radiotherapy; and the final one is the first drug tested for cancer immunotherapy," says E. David Crawford, MD, investigator at the University of Colorado Cancer Center and head of urologic oncology at University of Colorado Hospital.

"Even without the addition of any more drugs, we may now have the tools that in combination will allow us to extend the survival prognosis of a prostate cancer patient long enough to make prostate cancer a disease a patient is more likely to die with than from," Crawford says.

Along with Thomas Flaig, MD, Crawford describes these advances in prostate cancer treatment in a recent review for the journal Oncology.

First is the drug Denosumab, which Crawford says, "has three uses in protecting the bones of prostate cancer patients." It can prevent bone fractures in patients with existing bone metastasis; it can prevent osteoporosis in patients whose calcium is depleted as a side-effect of hormone therapy; and (pending FDA approval) it has been shown to hold off the occurrence of bone metastasis for an average of four months in patients whose spiking PSA scores predict the likely onset of bone involvement.

Second is the drug Alpharadin, which is one of a novel and exciting class of "radiopharmaceuticals" drugs that emit radiation and allow doctors to precisely deliver radiation to tumor sites. In the case of Alpharadin, it emits alpha rather than beta particles, which allows more precise tumor targeting of bone metastasis sites with less collateral damage to surrounding bone marrow.

Third, the drug Prostvac is the first "immunotherapy" drug used for the treatment of cancer. The drug acts like a vaccine, priming the immune system to recognize and thus fight against prostate cancer cells. In a phase II clinical trial of 125 patients, the drug extended the median survival time from 16.6 to 25.1 months.

Finally, the drug Abiraterone Acetate completely suppresses the body's ability to make testosterone, which many prostate cancers need to grow (as opposed to previous drugs, which hoped to out-compete testosterone with estrogen, or imperfectly controlled testosterone production).

Crawford notes that these drugs are being approved for use only after more established therapies have failed and hopes that in coming years science may accelerate the use of these drugs to first-line therapies.

E. David Crawford, MD, investigator at the University of Colorado Cancer Center

"Before we just had hormone therapy, then we got chemo, and each therapy we added packed on another couple months of survival. Now with these news drugs we're tacking on even more time. The light at the end of the tunnel is the hope that we'll turn this into a chronic disease and now we might have the tools that in some combination will do it," Crawford says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs
2. New smart nanotherapeutics can deliver drugs directly to the pancreas
3. Drugs used to overcome cancer may also combat antibiotic resistance: McMaster researchers
4. Silk microneedles deliver controlled-release drugs painlessly
5. Researchers develop more effective way to discover and test potential cancer drugs
6. Parkinsonian worms may hold the key to identifying drugs for Parkinsons disease
7. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
8. Discovery announced in Science represents new paradigm in the way drugs can be manufactured
9. Potential new drugs plug brains biological vacuum cleaner and target HIV
10. Can antivirulence drugs stop infections without causing resistance?
11. Worm cell death discovery could lead to new drugs for deadly parasite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... As the call for ... industry stakeholders, the discussion surrounding the topic will continue at WEDI 2017- Driving ... Los Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange (WEDI), the ...
(Date:4/25/2017)... ... 25, 2017 , ... L3 Clinical Trials, the Clinical Research ... now a certified iMedNet eClinical and Electronic Data Capture software designer for clinical ... team to build, customize and manage clinical trial data capture and databases for ...
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum Review ... be featured in multiple sessions at this week’s Association of Clinical Research Professionals ... best practices in clinical research. , "We are excited to present subject matter expertise ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Having worked on ... year, Formaspace is pleased to introduce it to top lab design architects from around ... Jeff Turk and VP of Industrial Design and Engineering Greg Casey will be at ...
Breaking Biology Technology: